TABLE 1.

Clinical and demographic characteristics of subjects with LPL CNVs

	Subject 1	Subject 2	Subject 3	Subject 4
Age	53	48	64	46
Gender	Male	Male	Male	Female
Weight (kg)	91.7	86.4	101.0	91.9
Height (cm)	174	173	180	163
Ethnicity	Northern European (Anglo-Saxon); Hispanic	Northern European (Anglo-Saxon)	Northern European	Caucasian
Total cholesterol (mmol/l)	10.1	4.98	7.54	17.4
TG (mmol/l)	36.1	16.7	35.9	36.4
HDL cholesterol (mmol/l)	0.59	0.76	0.45	0.39
LDL cholesterol (mmol/l)	1.76	Not determined	Not determined	1.24
apo B (g/l)	1.28	0.69	0.84	4.44
Fasting glucose (mmol/l)	10.0	6.3	10.0	11.0
HbA1c, normal <6.0%	6.8%	6.1%	8.0%	5.6%
ALT (U/l), normal <45 U/l	35	53	18	83
TSH (U/l), normal <4 U/l	1.75	2.18	3.4	1.34
Co-morbidities and other conditions	Acute pancreatitis ×3; pancreatic pseudocyst; type 2 diabetes; carotid and aortoiliac plaque; hepatic steatosis; gout; historically highest TG was 102 mmol/l (9,000 mg/dl)	Herpes zoster; impaired glucose tolerance; hepatosteatosis	Acute pancreatitis ×3; type 2 diabetes; CABG; MI ×2; gout	Acute pancreatitis; gallstones (cholecystectomy)
Medications	Insulin; canagliflozin; pioglitazone; intermittent fasting; gemfibrozil; testosterone supplement	Rosuvastatin; fenofibrate	Gemfibrozil; rosuvastatin; canagliflozin; insulin; metformin; metoprolol; ramipril; amlodipine; acetylsalicylic acid; allopurinol	Gemfibrozil
Identified genetic determinants	LPL exon 1 deletion (heterozygous); common LPL p.D36N variant (heterozygous); normal polygenic risk score (<64th percentile)	LPL exon 1-2 deletion (heterozygous); normal polygenic risk score (<43rd percentile)	LPL exon 1-2 deletion (heterozygous); normal polygenic risk score (<77th percentile)	LPL exon 1-2 deletion (heterozygous); normal polygenic risk score (<31st percentile)

Values provided are from first presentation to specialist lipid clinic or date first obtained. ALT, alanine transaminase; CABG, coronary artery bypass graft; HbA1c, hemoglobin A1C; MI, myocardial infarction; TSH, thyroid stimulating hormone.